Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multi-Center, Double-Masked, Randomized, Placebo Controlled, Study on the Safety and Efficacy of RX-10045 on the Signs and Symptoms of Dry Eye in Every Day Environmental Conditions and During Provocation Using the Controlled Adverse Environment (CAE) Model

NCT00799552 is registered in ClinicalTrials.gov with Resolvyx Pharmaceuticals, Inc as lead sponsor.

NCT NCT00799552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00799552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multi-Center, Double-Masked, Randomized, Placebo Controlled, Study on the Safety and Efficacy of RX-10045 on the Signs and Symptoms of Dry Eye in Every Day Environmental Conditions and During Provocation Using the Controlled Adverse Environment (CAE) Model
Lead sponsor
Resolvyx Pharmaceuticals, Inc
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2008
Completion date
June 30, 2009
Enrollment
232 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dry eye syndrome